Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ATHE

Alterity Therapeutics Ltd ADR

Jun 17 • 04:00PM ET

4.33

Dollar change -0.09
Percentage change -1.93	%

Healthcare • Biotechnology • Australia • NASD

Peers: BIIB ABBV PRTA ACAD SAVA IONS ANVS INMB LXRX LPTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.58	Insider Own	4.67%	Shs Outstand	15.21M	Perf Week	-6.48%
Market Cap	65.86M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	14.50M	Perf Month	8.52%
Income	-13.05M	PEG	-	EPS next Q	-	Inst Own	1.59%	Short Float	0.88%	Perf Quarter	13.05%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-7.61%	Short Ratio	3.25	Perf Half Y	101.40%
Book/sh	0.54	P/B	7.96	EPS next Y	-	ROA	-120.38%	Short Interest	0.13M	Perf Year	134.05%
Cash/sh	0.18	P/C	23.44	EPS next 5Y	-	ROE	-154.88%	52W Range	1.00 - 5.87	Perf YTD	30.82%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.86%	ROIC	-269.12%	52W High	-26.24%	Beta	0.75
Dividend TTM	-	Quick Ratio	3.84	Sales past 5Y	-	Gross Margin	-	52W Low	332.57%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	3.84	EPS Y/Y TTM	20.25%	Oper. Margin	-	RSI (14)	48.94	Volatility	1.87% 3.14%
Employees	10	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	12.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	47.40%	Payout	-	Rel Volume	0.10	Prev Close	4.41
Sales Surprise	-97.00%	EPS Surprise	18.38%	Sales Q/Q	-	Earnings	Feb 28 BMO	Avg Volume	39.32K	Price	4.33
SMA20	-3.57%	SMA50	9.36%	SMA200	54.56%	Trades		Volume	4,070	Change	-1.93%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-03-25	Downgrade	The Benchmark Company	Speculative Buy → Hold
Dec-12-24	Initiated	Maxim Group	Buy	$8

May-12-25 07:35AM	Alterity Therapeutics Prominently Featured at the International MSA Congress (GlobeNewswire) -8.54%
May-07-25 08:16AM	Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress (GlobeNewswire)
May-05-25 07:35AM	Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy (GlobeNewswire) +26.45%
Apr-30-25 07:35AM	Appendix 4C Q3 FY25 Quarterly Cash Flow Report (GlobeNewswire)
Apr-28-25 07:35AM	Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium (GlobeNewswire)
07:35AM	Loading…
Apr-10-25 07:35AM	Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting (GlobeNewswire)
Apr-03-25 07:35AM	Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting (GlobeNewswire) -5.39%
Mar-27-25 07:25AM	Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy (GlobeNewswire)
Feb-10-25 07:25AM	Alterity Therapeutics Raises A$40.0 million in Placement (GlobeNewswire) +8.71%
Jan-30-25 07:35AM	Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy (GlobeNewswire) +57.04%
Jan-24-25 07:35AM	Appendix 4C Q2 FY25 Quarterly Cash Flow Report (GlobeNewswire) -11.98%
Jan-10-25 07:35AM	Alterity CEO says filled with optimism for 2025 (TipRanks)
Jan-09-25 07:25AM	Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones (GlobeNewswire)
Dec-04-24 07:35AM	Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy (GlobeNewswire) +17.49%
Nov-19-24 07:25AM	Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary (GlobeNewswire)
07:35AM	Loading…
Nov-12-24 07:35AM	Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium (GlobeNewswire)
Nov-06-24 07:35AM	Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434 (GlobeNewswire)
Oct-31-24 07:35AM	Appendix 4C Q1 FY25 Quarterly Cash Flow Report (GlobeNewswire)
Oct-14-24 07:35AM	Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024 (GlobeNewswire)
Oct-11-24 07:35AM	Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting (GlobeNewswire)
Oct-02-24 07:35AM	Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
Sep-30-24 07:35AM	Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer (GlobeNewswire)
Sep-23-24 07:35AM	Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
Jul-31-24 07:35AM	Appendix 4C Q4 FY24 Quarterly Cash Flow Report (GlobeNewswire)
Jul-24-24 07:35AM	Alterity Therapeutics to Present at MST Financial Webinar (GlobeNewswire)
Jul-18-24 11:01AM	Alterity (ATHE) Up on Interim Data From Advance MSA Study (Zacks) -11.01%
Jul-17-24 07:35AM	Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire) +6.34%
Jun-12-24 07:22PM	Alterity Therapeutics to Present at the MST Access 'Hidden Gems in Life Sciences' Webinar (GlobeNewswire)
May-29-24 07:21PM	Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study (GlobeNewswire)
May-08-24 07:25AM	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review (GlobeNewswire)
07:25AM	Loading…
Apr-30-24 07:25AM	Appendix 4C Q3 FY24 Quarterly Cash Flow Report (GlobeNewswire)
Apr-29-24 07:25AM	Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia (GlobeNewswire) -12.55%
Apr-17-24 07:25AM	Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Apr-10-24 07:25AM	Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 (GlobeNewswire) +14.66%
Mar-26-24 10:25AM	Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund (GlobeNewswire) +5.26%
Feb-20-24 10:25AM	Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
Feb-06-24 07:25AM	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review (GlobeNewswire)
Jan-29-24 07:24AM	Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week (GlobeNewswire) +5.53%
Jan-22-24 07:25AM	Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones (GlobeNewswire)
Dec-21-23 12:30AM	Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer (GlobeNewswire)
Dec-04-23 04:35PM	Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress (GlobeNewswire) +153.01% -22.86%
02:15PM	Why Is Alterity Therapeutics (ATHE) Stock Up 150% Today? (InvestorPlace)
07:25AM	Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease (GlobeNewswire)
Nov-27-23 07:25AM	Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy (GlobeNewswire) -6.49%
Nov-16-23 07:25AM	Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434 (GlobeNewswire)
Nov-08-23 07:25AM	Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire) +12.77%
Oct-30-23 07:25AM	Appendix 4C Q1 FY24 Quarterly Cash Flow Report (GlobeNewswire) -5.98%
Aug-31-23 07:25AM	Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder (GlobeNewswire)
Aug-23-23 07:25AM	Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinsons and Alzheimers (GlobeNewswire)
Aug-22-23 07:25AM	Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinsons Disease and Movement Disorders (GlobeNewswire)
Aug-15-23 07:25AM	Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund (GlobeNewswire)
Jul-31-23 07:52AM	Appendix 4C Q4 FY23 Quarterly Cash Flow Report (GlobeNewswire)
Jul-26-23 07:25AM	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned (GlobeNewswire) +6.49%
Jun-21-23 07:25AM	Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023 (GlobeNewswire)
May-30-23 07:25AM	Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder (GlobeNewswire) +6.51%
May-19-23 07:25AM	Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023 (GlobeNewswire)
May-10-23 07:25AM	Appendix 4C Q3 FY23 Quarterly Cash Flow Report (GlobeNewswire)
07:25AM	Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire)
Apr-26-23 07:25AM	Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology (GlobeNewswire)
Apr-04-23 07:25AM	Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire)
Mar-16-23 07:25AM	Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire) +6.70%
Mar-14-23 07:25AM	Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimers Disease (GlobeNewswire) -7.14%
Mar-08-23 07:25AM	Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire)
Feb-16-23 04:44PM	Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial (GlobeNewswire) +7.64%
Jan-31-23 07:25AM	Appendix 4C - Q2 FY23 Quarterly Cash Flow Report (PR Newswire) -5.78%
Jan-30-23 07:25AM	Alteritys ATH434 Prevents Loss of Brain Cells in Parkinsons Disease Animal Model (GlobeNewswire) +6.14%
Jan-25-23 07:25AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy (GlobeNewswire)
Jan-20-23 09:40AM	Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-09-23 10:25AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy (PR Newswire)
Jan-06-23 07:25AM	Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) (PR Newswire)
Jan-03-23 10:25AM	Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (PR Newswire)
Dec-29-22 10:25AM	Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office (PR Newswire) +16.91%
Nov-07-22 10:25AM	Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting (PR Newswire)
Oct-28-22 07:25AM	Appendix 4C - Q1 FY23 Quarterly Cash Flow Report (PR Newswire)
Oct-26-22 07:25AM	Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting (PR Newswire)
Oct-13-22 10:25AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy (PR Newswire)
Sep-26-22 07:25AM	Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders (PR Newswire)
Sep-20-22 07:25AM	Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy (PR Newswire) -10.71%
Aug-25-22 07:25AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe (PR Newswire)
Aug-08-22 04:00PM	Is Alterity Therapeutics (ASX:ATH) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jul-22-22 07:25AM	Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report (PR Newswire)
Jul-06-22 11:00AM	Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (PR Newswire)
Jun-24-22 08:35AM	Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing (GlobeNewswire)
Jun-23-22 11:00AM	Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy (PR Newswire) +5.24%
Jun-21-22 04:21PM	UPDATE - Life Sciences Investor Forum: Company Executives Present Live June 23rd (GlobeNewswire)
08:35AM	Life Sciences Investor Forum: Company Executives Present Live June 23rd (GlobeNewswire)
Jun-20-22 07:05AM	Alterity Therapeutics to Present at the VirtualInvestorConferences.com Life Sciences Investor Forum (GlobeNewswire)
Jun-02-22 08:00AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy (PR Newswire)
May-31-22 08:27AM	Safe-T Group Reports Record First Quarter 2022 Results with Revenues of $4.02 Million, Up 199% Over First Quarter 2021 Results (GlobeNewswire)
Apr-27-22 07:40AM	Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom (PR Newswire)
Apr-06-22 09:34PM	Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting (PR Newswire)
Jan-28-22 11:02AM	Alterity Therapeutics Highlights New Publications On ATH434 In Parkinson's Disease (Benzinga) +8.95%
07:08AM	Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease (PR Newswire)
Jan-27-22 07:45AM	Appendix 4C - Q2 FY22 Quarterly Cash Flow Report (PR Newswire)
Jan-06-22 07:30AM	Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's (PR Newswire) +33.85%
Jan-05-22 07:45AM	Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (PR Newswire)
Dec-14-21 07:25AM	Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial (PR Newswire)
Nov-22-21 07:50AM	Alterity Therapeutics to Participate in Two Upcoming Investor Conferences (PR Newswire) -5.56%
Nov-09-21 07:30AM	Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021 (PR Newswire)
Nov-05-21 02:57AM	Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases (PR Newswire)

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson's, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATHE

Alterity Therapeutics Ltd ADR

Upgrade your FINVIZ experience